Obinutuzumab
Gazyva · Anti-CD20 antibody (type II) · CD20
Glycoengineered type II anti-CD20 antibody with enhanced antibody-dependent cellular cytotoxicity compared to rituximab.
Used in combination regimens for MCL, particularly with venetoclax and BTKi
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Cancer · Apr 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 2026
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.
Blood research · Aug 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.
British journal of haematology · Jun 2025
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Clinical lymphoma, myeloma & leukemia · Mar 2025
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Blood · Jan 2025
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jan 2025
Two B or not two B; the question of bendamustine dosing in low grade lymphoma.
Pathology oncology research : POR · Jan 2025
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.
Blood · Dec 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Blood · Jul 2024